Performance differences seen in continuous glucose monitors

Performance differences seen in continuous glucose monitors
Continuous glucose monitoring devices vary in performance characteristics, according to a comparative effectiveness study published online Dec. 28 in Diabetes Care.

(HealthDay)—Continuous glucose monitoring (CGM) devices vary in performance characteristics, according to a comparative effectiveness study published online Dec. 28 in Diabetes Care.

Edward R. Damiano, Ph.D., from Boston University, and colleagues recruited six patients with (age 52 ± 14 years) to participate in two 51-hour closed-loop blood glucose control experiments. Subjects simultaneously wore three CGM devices—the Navigator (Abbott ), the Seven Plus (DexCom), and the Guardian ()—to obtain CGM glucose (CGMG) measurements. Measurements were paired with corresponding venous (PG) measurements (GlucoScout, International Biomedical) obtained every 15 min (2,360 values).

The researchers found that the Navigator had the best overall accuracy, with an aggregate mean absolute relative difference (MARD) of all paired points (PG-CGMG measurements) of 11.8 ± 11.1 percent and an average MARD across all 12 experiments of 11.8 ± 3.8 percent. The Seven Plus had an aggregate MARD of all paired points of 16.5 ± 17.8 percent and an average MARD across all 12 experiments of 16.5 ± 6.7 percent. For the Guardian, the corresponding figures were 20.3 ± 18.0 percent and 20.2 ± 6.8 percent. Reliability, as measured by data reporting percentages, was 76 percent for the Seven Plus and close to 100 percent for the Navigator and Guardian.

"The results of this head-to-head-to-head study reveal the Navigator was the most accurate and precise of the current generation of CGM devices, followed by the Seven Plus and the Guardian," the authors write.

International Biomedical provided GlucoScout monitors and technical assistance regarding their use.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

ADA: Hypo-hyperglycemia minimizer system feasible

Jun 12, 2012

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes ...

MU researchers pioneer animal diabetes treatment

Apr 25, 2011

Studies show the incidence of diabetes in dogs has increased 200 percent over the past 30 years. Now, University of Missouri veterinarians have changed the way veterinarians treat diabetes in animals by adapting ...

Recommended for you

User comments